Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Shares of Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BOSTON--(BUSINESS WIRE)--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX). WHOOP Advanced Labs combines comprehensive blood testing, clinician-reviewed results, AI-powered insights, and personalized recommendations to give people a d.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.

Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. “You get used to it.

Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #ai #artificialintelligence #health #healthcare #technology #medical #patients #doctors #diagnostics #innovation #business #leadership #future #medicine #jimdavis #questdiagnostics